Nika Pharmaceuticals, Inc. (NIKA)
OTCMKTS · Delayed Price · Currency is USD
0.6900
0.00 (0.00%)
At close: Jun 12, 2025

Nika Pharmaceuticals Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Cash & Equivalents
0.0200.02000
Cash & Short-Term Investments
0.0200.02000
Cash Growth
-21.78%-89.37%2168.06%116.54%-75.23%-
Prepaid Expenses
0.020.02----
Total Current Assets
0.030.020.02000
Total Assets
0.030.020.02000
Short-Term Debt
0.270.240.10.02--
Other Current Liabilities
----0.01-
Total Current Liabilities
0.270.240.10.020.01-
Other Long-Term Liabilities
----0.010.01
Total Liabilities
0.270.240.10.020.020.01
Common Stock
0.10.10.090.090.040.01
Additional Paid-In Capital
8.68.63.233.230.090.11
Retained Earnings
-8.94-8.93-3.4-3.34-0.15-0.14
Total Common Equity
-0.24-0.22-0.08-0.02-0.02-0.01
Shareholders' Equity
-0.23-0.22-0.08-0.02-0.02-0.01
Total Liabilities & Equity
0.030.020.02000
Total Debt
0.270.240.10.02--
Net Cash (Debt)
-0.25-0.24-0.08-0.0200
Net Cash Growth
-----75.23%-
Net Cash Per Share
-0.00-0.00-0.00-0.00--
Filing Date Shares Outstanding
1,0261,026876.09876.09396.09396.09
Total Common Shares Outstanding
1,0261,019876.09876.09396.09396.09
Working Capital
-0.23-0.22-0.08-0.02-0.010
Book Value Per Share
-0.00-0.00-0.00-0.00-0.00-0.00
Tangible Book Value
-0.24-0.22-0.08-0.02-0.02-0.01
Tangible Book Value Per Share
-0.00-0.00-0.00-0.00-0.00-0.00
Updated Nov 12, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.